Company profile: ProStrakan
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical development and commercialisation of prescription medicines for unmet therapeutic needs in major markets; headquartered in Scotland with more than 300 employees and commercial operations.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProStrakan
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
Normax Biomed
HQ: Ireland
Website
- Description: Provider of mRNA vaccine R&D and manufacturing for infectious diseases such as tuberculosis and HIV. Delivers Vax Factory, a modular solution for rapid, scalable production; leads the mRNA UCV Consortium; and runs GOAL 2050 to end TB and HIV transmission via mRNA vaccines, affordable treatments, and education, supporting the SDG for good health & well being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normax Biomed company profile →
Abac Therapeutics
HQ: Spain
Website
- Description: Provider of precision antimicrobial drug discovery and development, creating first-in-class, pathogen-specific antibiotics for MDR Gram-negative infections. Offers the PasNas scalable, multiplexed platform to identify high-quality leads across compounds and bacterial species, and advances agents with suitable pharmacokinetics/toxicology, leveraging public-private collaborations to combat antimicrobial resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abac Therapeutics company profile →
Iterum Therapeutics
HQ: Ireland
Website
- Description: Provider of clinical-stage anti-infectives targeting multi-drug resistant pathogens. Offers sulopenem, an oral and IV penem antibiotic with broad-spectrum activity against multi-drug resistant gram-negative infections in hospital and community settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iterum Therapeutics company profile →
Atriva Therapeutics
HQ: Germany
Website
- Description: Provider of host-targeting antiviral therapies for respiratory viral infections. Its lead candidate, zapnometinib (ATR-002), is an orally available small molecule designed to inhibit viral replication and modulate immune response to treat severe RNA-virus infections. Completed a Phase I safety study; assessing efficacy and safety in a Phase II study in hospitalized severe COVID-19 and planning Phase II development for severe influenza.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atriva Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProStrakan
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProStrakan
2.2 - Growth funds investing in similar companies to ProStrakan
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProStrakan
4.2 - Public trading comparable groups for ProStrakan
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →